The European Medicines Agency Committee for Medicinal Products for Human Use issued a positive opinion for Imbruvica (ibrutinib) for the treatment of adult patients with previously-untreated chronic lymphocytic leukemia. The positive CHMP recommendation follows the March 2016 FDA approval of Imbruvica for the first-line treatment of patients with CLL. If approved by the European Commission,...
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
